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Abstract
The ectodomain of the matrix 2 protein (M2e) of influenza A virus represents an attractive target for developing a universal
influenza A vaccine, with its sequence being highly conserved amongst human variants of this virus. With the aim of
targeting conformational epitopes presumably shared by diverse influenza A viruses, a vaccine (M2e-NSP4) was constructed
linking M2e (in its consensus sequence) to the rotavirus fragment NSP498–135; due to its coiled-coil region this fragment is
known to form tetramers in aqueous solution and in this manner we hoped to mimick the natural configuration of M2e as
presented in membranes. M2e-NSP4 was then evaluated side-by-side with synthetic M2e peptide for its immunogenicity
and protective efficacy in a murine influenza challenge model. Here we demonstrate that M2e fused to the tetramerizing
protein induces an accelerated, augmented and more broadly reactive antibody response than does M2e peptide as
measured in two different assays. Most importantly, vaccination with M2e-NSP4 caused a significant decrease in lung virus
load early after challenge with influenza A virus and maintained its efficacy against a lethal challenge even at very low
vaccine doses. Based on the results presented in this study M2e-NSP4 merits further investigation as a candidate for or as
a component of a universal influenza A vaccine.
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Introduction
Seasonal Influenza A epidemics represent a major threat to the
human population worldwide causing three to five million cases of
severe illness and about 250,000–500,000 deaths each year (WHO
website: http://www.who.int/mediacentre/factsheets/fs211/en/
index.html). In addition, there is the constant threat of a pandemic
influenza outbreak. Currently available vaccines against seasonal
epidemics are efficient as long as there is a good match between
the chosen vaccine strains and circulating influenza variants.
However, these vaccines target the surface molecule hemaggluti-
nin (HA) and to a lesser extent neuraminidase (NA), and due to the
continuous change of these proteins because of mutations and
antibody mediated selection, these vaccines need to be updated
annually [1]. It is therefore of substantial interest to develop
a vaccine that would cross-react between different influenza A
virus subtypes and could be used to protect against unpredicted
antigenic variation in both epidemic and pandemic outbreaks.
Clearly, this type of vaccine should target a conserved viral
protein. One promising candidate is the ectodomain of the matrix
2 protein (M2e). The M2 protein is a small protein of 97 amino
acids (aa) functioning as a tetrameric ion channel. M2 is involved
in uncoating of viral particles in the endosomes and in the
maturation of HA in the Golgi apparatus [2]. M2e consists of
23 aa and serves as an attractive target due to the fact that it is
highly conserved amongst human influenza A viruses, and with
two exceptions no amino-acid change has been found until
recently when 4 mutations were identified in the pandemic A
California virus [3–6]. In addition, M2e-specific antibodies have
been found to protect mice, ferrets and non-human primates [7–
11]. The M2 protein is expressed in low quantities on influenza
viral particles, but it is abundantly expressed on the plasma
membranes of infected cells [12]. M2e in itself is poorly
immunogenic [13] and various strategies have been applied to
improve its immunogenicity such as constructing peptide carrier
conjugates [8], multiple antigenic peptides (MAPs) [14,15], M2e-
Hepatitis B virus core (M2e-HBc) conjugates [7], recombinant
fusion proteins [9,16], DNA constructs [17], DNA prime-viral
boost combinations [18], and delivering combined M2e peptide
and split virus [19].
As already mentioned, the natural configuration of M2 is as
a tetrameric structure. We were interested in constructing a vaccine
based on the native structure of M2 since both monoclonal
antibodies [20,21] against conformational epitopes and a vaccine
[16] targeting conformational epitopes of the M2 protein have
been proven to afford clinical protection. We therefore replaced
the transmembrane part and the cytoplasmic tail of M2 with the
NSP498–135 fragment of rotavirus, which due to its coiled-coil
region is known to form tetramers in aqueous solution [22]. The
fused construct was successfully expressed in Escherichia coli (E. coli).
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For functional analysis, the recombinant fusion protein M2e-NSP4
was compared head-to-head to synthetic M2e peptide, which is the
basis for several other M2e targeting vaccines. Here we
demonstrate that the vaccine construct M2e-NSP4 is superior to
M2e peptide immunization when both are formulated in the
liposome based cationic adjuvant CAF-01 [23–26], inducing more
cross-reactive antibodies and more antibodies that can recognize
the native M2 protein. Furthermore, compared to mice immu-
nized with M2e peptide, M2e-NSP4 vaccination significantly
reduced both the early viral load in the lungs and the mortality of
mice infected with a homologous virus.
Materials and Methods
Ethics Statement
Experiments were conducted in accordance with national
Danish guidelines (Amendment # 1306 of November 23, 2007)
regarding animal experiments as approved by the Danish Animal
Experiments Inspectorate, Ministry of Justice, permission numbers
2004/561–867 and 2009/561–1679.
Recombinant M2e-NSP4 Cloning and Expression
A construct encoding M2e, originating from the human
influenza consensus sequence [11], linked to the NSP498–135
fragment of rotavirus, was chemically synthesized with optimized
E. coli codons (GenScript, NJ). The DNA was amplified from the
pUC57 vector (GenScript, NJ) and the polymerase chain reaction
(PCR) product was digested with the restriction enzymes NdeI and
BamHI (both from Fermentas, Burlington, Ontario) and ligated
into a pET11a vector (Novagen, San Diego, CA), which had been
digested with the same enzymes. The ligation mixture was
electrotransformed into B834(DE3) cells (Novagen, San Diego,
CA). Positive clones were confirmed by DNA sequencing
(Eurofins, MWG Operon, Germany). The plasmid DNA was
then used for retransformation into the same cells and the cultures
were grown overnight. The cultures were harvested 3–4 hours
after induction with 1 mM IPTG.
Protein Purification
The bacterial cultures carrying the plasmid pET11a/M2e-
NSP4 were grown in LB medium containing 50 mg/mL ampicillin
until OD600 reached 0.4–0.6. Thereafter, 1 mM IPTG was added
for induction for 3–4 hours at 37uC. The cells were harvested by
centrifugation at 50006g for 5 min and resuspended in 50 mM
Tris, 50 mM NaCl, pH 7.5. This was followed by centrifugation
of the cells at 50006g for 5 min. The supernatants were removed
and the pellets were stored at 220uC.
The proteins were purified using nickel affinity chromatogra-
phy. Specific measures were taken for purification of M2e-NSP4
as this protein only had an HVH-tag positioned at the end of the
NSP4 fragment sequence. The bacteria were resuspended in 5 mL
of 25 mM Tris, pH 8.0, and sonicated 3630 s on ice. The
suspensions were centrifuged at 18000 rpm615 min in the cold.
The supernatants were applied to a Tricorn 10/50 column (GE
Healthcare, UK), which had been packed with 5 mL nickel-
nitrilotriacetic acid (Ni-NTA) (Qiagen). The columns were washed
with 1 column volume of 25 mM Tris, pH 8.0, and eluted with
25 mM Tris, 250 mM imidazole, pH 8.0 0–100% over 1 column
volume. The relevant fractions were pooled and loaded directly on
MonoQ 10/100 columns (Qiagen). The columns were washed
with 1 column volume 50 mM Tris, pH 7.5, and the proteins were
eluted with 0–1 M NaCl over 5 column volumes. The fractions
were stored at 220uC. Analysis on the fractions was done with
SDS-PAGE stained with Coommassie Blue A band corresponding
to the M2e-NSP4 monomer could be visualized at 7 kDa (Fig. 1).
Further analysis of the relevant pooled fractions was done with
native PAGE (Fig. 2).
Endotoxin levels were determined using Kinetics Turbidimetric
LAL test (Charles River); endotoxin values of the purified protein
used in these experiments were ,4 EU/mg.
Peptides
The M2e peptides H-MSLLTEVETPTRSEWECRCSDSSDP-
OH (A/Ontario/309862/2009(swine-origin H1N1)), H-
MSLLTEVETPTRNEWECRCSDSSDP-OH (A/Indonesia/
560H/2006 (H5N1)), H-SLLTEVETPIRNEWGSRSNDSSDP-
OH (consensus H1N1), H-SLLTEVETPTKSEWESRSNVSSDL-
OH (A/equine/London/73 (H7N7)) and the NSP4 fragment H-
QMDRVVKEMRRQLEMIDKLTTREIEQVELLKRIYDKL-
Figure 1. Validation of M2e-NSP4 protein production and
purification. A) SDS-PAGE analysis of whole lysate and selected
fractions. All samples were run under reduced conditions. Lane 1:
molecular weight markers; lane 2: sonicate; lane 3–7: Ni-NTA fractions;
lane 8: MonoQ fraction. B) Native PAGE analysis of final pooled fractions.
Lane 1: a-Lactalbumin; lane 2: Carbonic Anhydrase; lane 3: Albumin
from chicken egg white; lane 4: Albumin from bovine serum; lane 5:
Urease; lane 6: M2e-NSP4.
doi:10.1371/journal.pone.0046395.g001
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OH were synthesized by Schafer-N (Copenhagen, Denmark).The
purity of the peptides was above 80% as analysed by HPLC and
mass spectrum.
2.4. Mouse Immunization
Female Balb/c mice were obtained from Taconic M&B (Ry,
Denmark), 6–8 weeks old, and housed at the Panum Institute,
University of Copenhagen. Mice were always allowed to
acclimatize for at least one week before entering into experiments.
All animal experiments were conducted in accordance with
national guidelines. Mice were immunized with the recombinant
fusion protein M2e-NSP4 or M2e peptide formulated with or w/o
CAF-01 adjuvant (SSI, Copenhagen, Denmark), Freund’s com-
plete (FCA) plus incomplete adjuvant (FIA) (Sigma-Aldrich) or
Alhydrogel adjuvant (Brenntag Biosector A/S Fredrikssund,
Denmark). Mice were immunized subcutaneously (s.c.) on days
0, 21, and 42. In some experiments, the immunization on day 42
was not performed. Blood samples were collected from the
submandibular vein two weeks after each vaccination. The blood
was allowed to clot prior to centrifugation, where after serum was
obtained.
Synthetic M2e Peptide ELISA
Nunc MaxisorbTM 96-well plates were coated overnight at 4uC
with 100 mL/well of 300 ng/mL M2e peptide in 50 mM bi-
carbonate buffer, pH 9.6. The plates were washed 16with PBS/
Tween (phosphate buffered saline (PBS) containing NaCl (0.35 M)
and 0.1% Tween-20, pH 7.4), and blocked for 1 hour at room
temperature (RT) with a 2.5% casein solution. For ELISA, all
plates were first washed 26 with PBS/Tween. The test samples
and reagents were diluted in dilution buffer (0.35 M NaCl, 75 mM
BSA, and 0.075% Tween in PBS, pH 7.2) at 100 mL/well and
incubated for 1 hour at RT. Bound mouse antibodies were
detected with HRP-labelled goat anti-mouse IgG antibodies (Fab-
specific) (Sigma-Aldrich), rat anti-mouse IgG1 antibodies (BD
PharMingen, San Diego, CA), rat anti-mouse IgG2a antibodies
(BD PharMingen, San Diego, CA), goat anti-mouse IgM
antibodies (Sigma-Aldrich) and goat anti-mouse IgA antibodies
(Sigma-Aldrich). The plates were washed 26 with PBS/Tween
and once with citric acid buffer (0.35 M C6H8O7.H2O and
0.67 M Na2HPO4.(H2O)2 in MilliQwater, pH 5) and then
incubated for 30 min at dark with 100 mL/well of substrate buffer
(citric acid buffer containing 0.7 mg/mL 1,2-phenylenediamine
dihydrochloride (Kementec Diagnostics, Taastrup, Denmark) and
0.4 mL/mL 30% H2O2). The reaction was stopped with 0.2 M
H2SO4 at 100 mL/well and the plates were read on the
MultiskanH FC microplate photometer from Thermo Scientific.
The antibody titer was defined as the reciprocal of the highest
dilution that yielded an OD490 nm value 4 times above the mean
value of the negative control wells.
HeLa-M2 ELISA
HeLa enzyme-linked immunosorbent assay (ELISA) plates
were prepared as follows: HeLa cells transfected with M2-
expressing plasmid (HeLa-M2) encoding a tetracycline response
element (Tet) and HeLa cells with an empty plasmid (HeLa-
C10) were obtained from Robert B. Couch [13]. The cells were
grown to confluency in Nunc MaxisorbTM 96-well plates by
seeding wells with 16105 HeLa cells in 150 mL of Iscove’s
Modified Dulbecco’s medium (Invitrogen) supplemented with 2-
mercaptoethanol at 0.05 mM, transferrin (Sigma-Aldrich) at
0.005 mg/mL, gentamicin (Riedel-de Hae¨n, Seelze, Germany)
at 0.05 mg/mL, and 10% fetal bovine serum (FBS) (Lonza,
Copenhagen, Denmark). The media was further supplemented
with 1 mg/mL doxycycline (Sigma-Aldrich) for induction of Tet.
After two days of incubation at 37uC in air/CO2, the media
was flicked out and the cells were fixed with 0.05%
glutaraldehyde (Sigma-Aldrich) for 20 min at RT. The plates
were washed 26 with PBS/Tween and blocked with dilution
buffer for 1 hour at RT or stored at 4uC. The test samples
were diluted 1:200 in dilution buffer at 50 mL/well and
incubated for 1 hour at RT. Bound mouse antibodies were
detected with HRP-labelled goat anti-mouse IgG antibodies
(Fab-specific) (Sigma-Aldrich), The plates were washed 26 with
PBS/Tween and 16 with citric acid buffer (0.35 M
C6H8O7.H2O and 0.67 M Na2HPO4.(H2O)2 in MilliQwater,
pH 5) and then incubated for 30 min at dark with 100 mL/well
with substrate buffer (citric acid buffer containing 0.7 mg/mL
1,2-phenylenediamine dihydrochloride (Kementec Diagnostics,
Taastrup, Denmark) and 0.4 mL/mL 30% H2O2). The reaction
Figure. 2. Comparison of the immunogenicity of M2e-NSP4 vs. M2e peptide and an evaluation of the importance of covalent
linkage between M2e and NSP4 in the M2e-NSP4 construct. Groups of Balb/c mice (n = 9–10) were immunized at days 0, 21, and 42 with
10 mg of either vaccine formulated in CAF-01. Serum samples were obtained 14 after each vaccination, i.e. at days 14 (1uvacc), 35 (2uvacc) and 56
(3uvacc) after primary vaccination, and analyzed in an ELISA for reactivity against M2e peptide. Results of individual sera are presented; group median
titres are indicated by horizontal bars. *denotes a p-value ,0.05; the data are representative of at least 5 experiments.
doi:10.1371/journal.pone.0046395.g002
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was stopped with 0.2 M H2SO4 at 50 mL/well and the plates
were read at A490 and A750 on the MultiskanH FC microplate
photometer from Thermo Scientific and the difference in
OD490–750 between the HeLa-M2 and the HeLa-C10 plates
was recorded. The difference between OD490–750 for HeLa-M2
and HeLa-C10 was recorded as DOD.
HeLa-M2 Flowcytometric Assay
HeLa-M2 cells and HeLa-C10 cells were maintained as stated
above. After 2 days of incubation with 1 mg/mL doxycycline
(Sigma-Aldrich), 56104 cells were added into wells of 96-well
round bottom micro-titer plates (Sigma-Aldrich). The cells were
washed twice with washing buffer (PBS, 1% BSA, 5% FCS).
Serum samples were added diluted 1:100 in washing buffer at
50 mL/well and incubated at 4uC for 30 min. The plates were
washed twice in washing buffer and the cells were incubated with
50 mL/well of FITC-conjugated Goat anti-mouse IgG2a specific
(Jackson ImmunoResearch), PE-conjugated Goat anti-mouse IgG
specific (Jackson ImmunoResearch) and APC-conjugated Goat
anti-mouse IgG1 specific antibodies in washing buffer at 4uC for
30 min. The cells were washed twice in washing buffer and once in
PBS. The cells were resuspended in 100 mL PBS and were
analysed on a FACSCalibur (BD Biosciences). Mouse sera positive
for all three stains and the monoclonal antibody 14C2 (Fisher
Scientific Pierce MA1-082, AH diagnostics, Aarhus, Denmark)
specific for M2e were used for instrument settings. A minimum of
10000 live cell events were normally collected. Data were analysed
using the FlowJo program, and the difference in mean fluores-
cence intensity (MFI) between HeLa-M2 and the HeLa-C10 cells
incubated with the same serum was recorded as DMFI.
Virus Challenge of Mice
For evaluation of clinical protection, mice immunized as
described above, were anaesthetized by intraperitoneal (i.p)
injection with 250–300 mL Avertin (25 mg/mL) and infected
intranasally (i.n.) with approx. 3 LD50 (dose lethal to 50% of mice)
of either A/equine/London/72 (H7N7) or A/Puerto Rico/34
(PR8, H1N1). Survival and weight was monitored for up to 3
weeks; mice suffering a weight loss greater than 25% of their
starting weight were euthanized for humane reasons.
Quantitative-Reverse-Transcriptase-Polymerase-Chain-
Reaction (QRT-PCR)
Viral loads were determined on 100 ng purified total RNA by
duplex QRT-PCR using the Brilliant QRT-PCR Master Mix
(Stratagene). Mice challenged with a lethal dose of PR8 were
sacrificed by cervical dislocation at day 3 post infection. Lungs
were removed and snap-frozen in either liquid nitrogen or dry ice.
The tissues were homogenized in 3.6 mL lysis buffer (Macherey-
Nagel, Du¨ren, Germany) using a polytron. The tissue lysates were
centrifuged twice at 3500 RPM for 10 min., and the supernatants
were transferred to new tubes in between and after the second
centrifugation. The clear tissue lysates were stored at 280uC.
RNA from the homogenized tissues was extracted according to the
standard kit extraction protocol from Nucleospin RNA II kit
(Macherey-Nagel, Du¨ren, Germany). RNA samples were quanti-
fied at 260 nm and qualitatively analysed by the 260/280 nm
ratio. The samples were stored at 280uC before further use.
The primers used were directed against the M gene (59
AGATGAGTCTTCTAACCGAGGTCG 39 and 59
TGCAAAAACATCTTCAAGTCTCTG 39) and the housekeep-
ing gene murine glyceraldehyde-3-phosphate dehydrogenase
(mGAPDH) (59 CAATGTGTCCGTCGTGGA 39 and 59
GATGCCTGCTTCACCACC 39). The following probes were
used, M2: FAM-TCAGGCCCCCTCAAAGCCGA-BHQ-1,
mGAPDH: HEX-CGCCTGGAGAAACCTGCCAAGTAT-
BHQ-1. The primers and the probes were synthesized by TAG
Copenhagen A/S. The primer and probe sequences for the M
gene had been previously published by Spackman et al [27]. The
cycling conditions were: 30 min at 50uC, 10 min at 95uC followed
by 40 cycles at 95uC for 30 s, 1 min at 58uC and 30 s at 72uC. All
samples were run in triplicates and a standard curve was included
in each run as an efficiency control of the amplification. A
paCCMV plasmid encoding the coding region of the M gene had
been previously constructed in the laboratory and was used for
absolute quantifications. The copy number was determined with
an optical density read out. The obtained results were analysed
using the Stratagene MxPro software.
Statistical Analysis
Antibody titers, viral titers, and MFIs were compared using the
two-tailed Mann-Whitney rank test. Survival curves are presented
as Kaplan-Meier plots and the statistical significance of differences
between groups was determined by the log-rank test with the
program GraphPad Prism (version 5.0).
Results
Purification of the M2e-NSP4 Protein
A construct containing the consensus sequence of M2e [11]
fused to the C-terminal of the NSP4 fragment was cloned and
expressed in E. coli. The fusion partner we have chosen has an
easily predictable coiled-coil sequence. Coiled-coil sequences are
known to be specific with respect to the number of subunits, and
both the full-length native NSP4 as well as the coiled-coil region
we have used as fusion partner for M2e are known to form stable
tetramers [22]. The cultures were grown for induction in
Erlenmayer shake flasks and the protein was purified by Ni-
NTA and MonoQ chromatography. The purity of the protein was
analysed by SDS-PAGE. Under reducing conditions, bands with
a molecular weight of approximately 7 kDa could be observed,
representing the monomer of the M2e-NSP4 construct (Fig. 1A).
The M2e-NSP4 fusion protein elutes slightly faster than the 29-
kDa carbonic anhydrase on a Superdex 75 gel filtration column,
which is expected for tetrameric M2e-NSP4 (data not shown), and
the native PAGE gel demonstrates that the protein is present as
a single specimen (Fig. 1B).
Immunogenicity of M2e and M2e-NSP4
To compare the immunogenicity of the recombinant fusion
protein to that of free peptide, mice were immunized with 10 mg of
antigen on days 0, 21 and 42, and sera collected 2 weeks after each
immunization were analyzed for M2e-specific IgG antibodies by
ELISA (Fig. 2). As standard adjuvant we chose CAF01, which is
a synthetic two-component liposome-based adjuvant comprising
the quaternary ammonium dimethyl-dioctadecyl-ammonium
(DDA) and the immune modulator trehalose 6,6’-dibehenate
(TDB) and likely to be approved for human use in the near future
[23–26]. M2e-NSP4 immunization induced higher antibody titers
after both the second and third immunization compared to M2e
immunization, though the difference was not statistically signifi-
cant.
In the same experiment we examined the requirement for
linking M2e to the NSP4 fragment, acquiring an oligomerized
construct, in order to obtain the same potency as seen with M2e-
NSP4 immunization. Mice were immunized with a mix of 10 mg
M2e and 10 mg of the NSP4 fragment and serum samples taken 2
Oligomerized M2e as an Influenza Vaccine
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weeks after each immunization were analyzed by ELISA. It was
evident that linkage significantly increased the immunogenicity to
M2e (Fig. 2).
The immunogenicity of the M2e-NSP4 vaccine was further
investigated by comparing immunization with 100 mg M2e to
50 mg of M2e-NSP4. Increasing the M2e peptide dose ten-fold led
to a marked increase in the antibody titer, which now matched
that in mice immunized with the linked construct (Figure S1).
However, increasing the M2e-NSP4 dose five-fold did not have
any significant effect, indicating that a dose of 10 mg per
immunization is optimal with this antigen. In summary, the
results show that M2e-NSP4 is more potent than M2e when
formulated in CAF-01, inducing a high antibody titer already after
two immunizations with 10 mg, and that a 5 times higher dose of
M2e-NSP4 does not further increase the response.
Next, the isotypes of the M2e and M2e-NSP4 M2e induced
antibodies after the third immunization were determined by
ELISA. The main isotypes that were induced by both M2e and
M2e-NSP4 immunization were IgG1, and to a lesser extent IgG2a
(Fig. 3). M2e-NSP4 induced a significantly higher IgG1 antibody
titer. No antibodies of the IgM or IgA isotypes were detected.
To test the efficacy of the CAF-01 adjuvant in comparison to
other adjuvants commonly used in mouse experiments, the two
vaccines were formulated with either CAF-01, AlOH, or FCA plus
FIA (Figure S2). Formulating either vaccine with FCA plus FIA
tended to increase the immunogenicity compared to CAF-01
formulation, while formulating the vaccines with AlOH did not.
Notably, irrespective of adjuvant formulation, M2e-NSP4 was
superior in immunogenicity to M2e.
In the case of unpredicted influenza outbreaks, it might be of
importance to spare on the available antigen. It was therefore
investigated if antigen sparing by either lowering the antigen dose
to 1 mg while preserving the immunization schedule or limiting the
number of doses to two while maintaining the antigen dose at
10 mg would affect the potency of either vaccine. As can be seen in
fig. 4, the M2e-NSP4 vaccine was superior in both cases, inducing
significantly higher antibody titers both after two and three
immunizations with 1 mg and after two immunizations with 10 mg
compared to the M2e vaccine.
Recognition of Native M2 in HeLa-M2 ELISA Assay
The results presented above showed that antibodies induced by
M2e as well as M2e-NSP4 immunization could react with
synthetic consensus M2e peptide. It was next investigated whether
the induced antibodies would also recognize the presumably native
M2 protein, as expressed on transfected HeLa cells (HeLa-M2
cells). HeLa-M2 cells and HeLa-C10 cells (for evaluation of non-
specific binding) were grown in 96-well plates in media
supplemented with doxycycline for two days. The cells were then
fixed and blocked, followed by incubation with individual serum
samples (diluted 1:200) obtained two weeks after the third
immunization. Figure 5 shows the compiled results of four
separate experiments. Matching what was observed in the ELISA
using synthetic M2e peptide, a larger proportion of the mice
immunized with M2e-NSP4 could recognize the native M2
protein compared to M2e immunized mice. Furthermore, sera
from M2e-NSP4 immunized mice reached significantly higher
median DOD values.
Flowcytometric Analysis of Native M2 Recognition
To confirm the above results and to investigate the isotype
composition of the antibodies recognizing cell-expressed M2
protein, a flow cytometric analysis was performed using individual
serum samples from the same four experiments analyzed above.
HeLa-M2 and HeLa-C10 cells were treated as previously
mentioned in the HeLa-M2 ELISA, and 56104 cells/well were
added into 96-well plates. Serum samples (diluted 1:100) were
added next, followed by staining with isotype specific immuno-
conjugates. As expected, a significantly higher total IgG DMFI was
observed for the M2e-NSP4 immunized mice (Fig. 6A, for
representative histograms see Figure S3). The predominant M2-
specific antibody isotype that was detected was IgG1 in both
vaccination groups (Fig. 6B). Several serum samples from both
M2e and M2e-NSP4 immunized mice were also found to contain
M2-specific antibodies of the IgG2a isotype, although with
a significantly higher median DMFI for M2e-NSP4 immunized
mice (Fig. 6C). These results together with the results presented
above indicate that the M2e-NSP4 vaccine is superior to M2e
peptide, inducing significantly more antibodies with specificity for
native M2 protein.
Figure 3. Isotype composition of M2e and M2e-NSP4 induced antibodies. Groups of Balb/c mice (n = 9–10) were immunized with 10 mg of
M2e peptide or M2e-NSP4 formulated in CAF-01at days 0, 21, and 42. Serum samples obtained on day 56 after primary vaccination were analyzed in
an ELISA for reactivity against M2e peptide. Results of individual sera are presented; group median titres are indicated by horizontal bars. *denotes
a p-value ,0.05.
doi:10.1371/journal.pone.0046395.g003
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Efficacy of M2e-NSP4 against Lethal Influenza Challenge
The ability of the vaccine to protect against a lethal influenza
virus challenge was first investigated in mice immunized s.c. at day
0, 21, and 42 with 10 mg M2e-NSP4 with and without CAF-01, or
with 1, or 0.1 mg M2e-NSP4 in CAF-01. Mice were challenged on
day 81 by i.n. administration of a lethal dose of influenza A PR8
and weight and survival was monitored for three weeks (Figure
S4). When formulated with CAF-01 the linked vaccine afforded
significant protection compared to control mice. Interestingly,
decreasing the dose of antigen ten-fold to 1 mg did not reduce the
efficacy of the vaccine.
To evaluate the efficacy of M2e-NSP4 compared to M2e,
groups of 9–10 mice were immunized three times with either
10 mg M2e or M2e-NSP4 s.c. and challenged with PR8 at day 69.
At 3 d.p.i., lungs were removed from 4–5 mice from each group
and from control mice for determination of lung viral titer with
QRT-PCR. The remaining mice were observed for weight
changes and survival. While no differences between M2e and
M2e-NSP4 immunized mice could be observed with regard to
weight change and survival (Fig. 7A and B), lung viral loads at 3
d.p.i. were found to be significantly lower in M2e-NSP4
immunized mice (Fig. 7C). This suggest that while the protection
induced by immunization with M2e is sufficient to protect mice
from severe weight loss and death, immunization with M2e-NSP4
seems to provide protection at an earlier stage causing also an
early reduction in viral load in the lungs.
Based on the encouraging results regarding analysis of viral load
in the lungs, we decided to truncate the immunization regimen to
investigate if this would lead to a difference also in survival rates.
Consequently, 2 separate experimental set-ups were evaluated
next. In the first, mice were immunized with the same dose as
previously described, but challenged i.n. with a lethal dose of PR8
already after the second immunization. In the second set-up, the
full sequence of the immunization protocol was applied, but the
antigen doses used for each vaccination were reduced by a factor
of 10 - from 10 to 1 mg. As can be seen in fig. 8, only half the
challenged mice survived a lethal challenge if the mice were
vaccinated only twice with the M2e peptide, whereas all but one
animal survived if the mice had been vaccinated twice with the
standard dose of M2e-NSP4 (fig. 8A and B). Even more clearly, if
the vaccine dose was reduced to one tenth of the original, nearly
all peptide vaccinated mice succumbed to an otherwise lethal
infection, while all but one M2e-NSP4 vaccinated mouse resisted
the challenge (fig. 8C and D). Taken together, these results
strongly support the idea that immunization with M2e in
Figure 4. Comparison of immunogenicity of M2e-NS4 vs. M2e
following truncation of the immunization regime. A) Groups of
Balb/c mice (n = 9–10) were immunized with 1 mg of M2e peptide or
M2e-NSP4 formulated in CAF-01at days 0, 21, and 42. Serum samples
were obtained 14 days after each vaccination, i.e. at day 14 (1uvacc), 35
(2uvacc) and 56 (3uvacc) after primary vaccination, and analyzed in an
ELISA for reactivity against M2e peptide. Results of individual sera are
presented; group median titres are indicated by horizontal bars.
*denotes a p-value ,0.05. B) Groups of Balb/c mice (n = 10) were
immunized with 10 mg of M2e peptide and M2e-NSP4 formulated in
CAF-01at days 0 and 21. Serum samples were obtained at day 14 (1u)
and 35 (2u) after primary vaccination and analyzed in an ELISA for
reactivity against M2e peptide. Results of individual sera are presented;
group median titres are indicated by horizontal bars. *denotes a p-value
,0.05.
doi:10.1371/journal.pone.0046395.g004
Figure 5. Reactivity of sera from M2e and M2e-NSP4 immu-
nized mice against HeLa cells expressing M2 protein. Balb/c
mice (n = 8–10/group/experiment) were immunized with 10 mg M2e
peptide or M2e-NSP4 formulated in CAF-01 at days 0, 21, and 42. Serum
samples harvested on day 56 after primary vaccination were analyzed in
a cellular ELISA for reactivity to M2 protein as expressed on HeLa cells.
Differences (D) in OD490–750 readings with M2 expressing and non-
expressing control cells is depicted. Sera from naı¨ve mice showed no
preferential binding to M2-expressing cells (DOD =,0) and are not
presented. Results of individual sera from 4 independent experiments
are presented; group median titres are indicated by horizontal bars.
*denotes a p-value ,0.05.
doi:10.1371/journal.pone.0046395.g005
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Figure 6. Reactivity of sera from M2e and M2e-NSP4 immu-
nized mice against HeLa cells expressing M2 protein. Balb/c
mice (n = 8–10/group/experiment) were immunized with 10 mg M2e
peptide or M2e-NSP4 formulated in CAF-01 at days 0, 21, and 42. The
isotype composition of M2-specific antibodies present in sera harvested
on day 56 after primary vaccination was analyzed using flow cytometric
analysis,differences in mean fluorescence intensitybetween M2-expres-
sing and non-expressing HeLa cells is depicted: (A) total IgG, (B) IgG1,
and (C) IgG2a. Results of individual sera from 4 independent
experiments are presented; group median titres are indicated by
horizontal bars. *denotes a p-value ,0.05.
doi:10.1371/journal.pone.0046395.g006
Figure 7. Comparison of the protection afforded by vaccina-
tion with M2e and M2e-NSP4 against challenge with an
influenza virus closely related to the vaccine. Balb/c mice
(n = 9–10/group) were immunized three times with 3 weeks interval
with either adjuvant alone (CAF-01), 10 mg of M2e or 10 mg of M2e-
NSP4 formulated in CAF-01. Around 4 weeks after last immunization the
mice were challenged with 3 LD50 of influenza A virus PR8, differing by
one amino acid from the M2e consensus sequence. The lungs from 4–5
mice from each group were removed for estimation of viral load 3 days
after infection and analyzed by quantitative PCR as described in
Materials and Methods (C). The remaining mice were monitored daily
for survival (B) and loss of body weight (A). The survival curves are
presented as Kaplan-Meier plots. *denotes a p-value ,0.05. Data are
representative of two experiments.
doi:10.1371/journal.pone.0046395.g007
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a tetramerized form induces substantially better clinical protection
than immunization with the monomeric peptide.
Cross-reactivity of Anti-M2 Antibodies
To explore whether immunization with M2e-NSP4 had the
potential to afford a broader protection against virus strains not
expressing the M2e consensus sequence, we assessed the cross-
reactivity of M2e-NSP4 and M2e induced antibodies in an
ELISA assay with different variants of synthetic M2e peptides.
Individual serum samples from the third immunization of
a representative experiment were tested for their reactivity to
consensus M2e, swine-origin H1N1 M2e, avian-origin H5N1
M2e, and equine H7N7 M2e. As can be seen in Table 1, the
swine and avian derived sequences differ by 4 and 3 amino
acids, respectively, from the consensus sequence, while the
equine sequence differs by 5 amino acids. As can be seen in
fig. 9, antibodies induced by M2e-NSP4 immunization were
significantly better at cross-reacting with the swine and equine
peptides but not the avian peptide than were antibodies from
M2e immunized mice. Taken together, these results imply that
M2e-NSP4 induces more broadly reactive antibodies and the
fusion vaccine might therefore potentially be effective against
a wider range of influenza A virus strains.
Finally, to determine if the M2e-NSP4 vaccine could protect
against infection with a heterosubtypic influenza virus, two groups
of mice were immunized three times s.c. with either 10 mg of M2e
or 10 mg of M2e-NSP4, and in two separate experiments these
mice were challenged with a lethal dose of H7N7, differing from
the M2e consensus sequence by 5 amino acids. Body weight
changes (data not shown) and survival were monitored during 16
days post challenge (Fig.10). It was observed that vaccination with
M2e-NSP4 tended to provide better protection against a hetero-
subtypic influenza infection although the difference was not
statistically significant with the numbers of mice investigated here.
Figure 8. Impact of dose reduction on the protection afforded by M2e and M2e-NSP4 vaccination against challenge with a closely
related influenza A virus. Balb/c mice (n = 9–10/group) were immunized either twice with 3 weeks intervals with 10 mg M2e or 10 mg M2e-NSP4 in
CAF-01(A and B), or three times with 3 weeks intervals with 1 mg M2e or 1 mg M2e-NSP4 in CAF-01(C and D). Control mice were left untreated.
Around 4–5 weeks after the last immunization all the mice were challenged with 3 LD50 of influenza virus PR8 and then monitored daily with regard
to survival (A and C) and loss of body weight (B and D). *denotes a p-value ,0.05.
doi:10.1371/journal.pone.0046395.g008
Table 1. Amino acid sequences from M2e.
Strain Subtype Origin Amino Acid Sequence*
Consensus H1N1 Human SLLTEVETPIRNEWGCRCNDSSD










*Sequences are compared to consensus, and mutations are indicated in bold.
doi:10.1371/journal.pone.0046395.t001
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Discussion
The trivalent influenza vaccine that includes the viral surface
proteins HA and NA, is the primary vaccine in use against
seasonal influenza epidemics. This vaccine is quite efficient at
inducing neutralizing antibodies, which can then protect against
the viral strains circulating during a specific season. However,
a vaccine that would not have to be updated every season would
have major economical and health benefits, particularly in
developing countries where annual vaccination is not easily
applicable. Recent studies have led to the discovery and targeting
of highly conserved regions in the HA protein showing significant
protective potential [28–30]. However, even if these candidates
seem promising, they still face the issue of only inducing group-
specific protection [31]. On the other hand, having a universal
vaccine solely based on the M2 protein is not without its problems
either, since there still does not exist a standardized protocol for
the ex vivo validation of the protection induced by M2 based
vaccines. This very substantially increases the cost involved in
introducing an M2–based vaccine on the market. However, thus
far, groups with promising M2 targeting candidates have steered
clear of this dilemma by including HA antigen in their vaccines
[19,32].
In this study we characterized and analyzed the potential of
a M2 vaccine construct intended to mimick the native structure of
M2e. Thus, consensus sequence M2e was fused to the NSP498–135
fragment of rotavirus, giving a fusion protein (M2e-NSP4) in
which the tetramerizing NSP4 fragment would structurally replace
the transmembrane section of the native M2 protein. This would
allow for four M2e fragments to aggregate and thus mimic the
native viral M2e conformation. When compared to M2e peptide
immunization in side-by-side analysis and with both vaccines
formulated in CAF-01 adjuvant, it was clearly revealed that M2e-
NSP4 was more immunogenic and could be used at lower doses
than the M2e peptide without loosing protective efficacy against
closely related influenza A virus challenge. At higher antigen
doses, both vaccines induced similar M2e peptide specific antibody
responses, though the early reduction of the lung viral titers in
PR8-challenged M2e-NSP4 immunized mice compared to M2e
peptide vaccinated mice could indicate that the more efficient
recognition of native M2 protein in the former mice might be
associated with better clinical protection.
As antibodies recognizing conformational epitopes might prove
to be more relevant in relation to in vivo protection, two assays
were used to analyze the reactivity of the induced antibodies to
native M2 protein as expressed on HeLa-M2 cells. It has
previously been demonstrated that assays using native M2 protein
as a basis for the assessment of vaccine-induced antibodies provide
more relevant information than M2e-peptide based assays [33].
The superiority of M2e-NSP4 that was implied in the M2e-peptide
ELISA assay became more evident in the two assays based on
HeLa cells expressing native M2 protein. In both the HeLa-M2
ELISA and the HeLa-M2 FACS assay, M2e-NSP4 was signifi-
cantly better at inducing M2 specific antibodies.
For a universal vaccine to be of any real relevance as an add-on
vaccine to the normal seasonal vaccine and/or as an interim
pandemic influenza vaccine it needs to be cross-protective. Several
attempts have been made to induce cross-reactive and therefore
cross-protective antibodies based on the highly conserved M2e
sequence. Although the M2e sequence is almost invariant within
human influenza A viruses there are several aa differences between
the human consensus sequence and avian sequences [34]. In
a study by Fan et al. the cross-reactivity of antibodies induced by
M2e-carrier constructs based on M2e sequences from the
consensus or the PR8 sequence were tested against several M2e-
Figure 9. Cross-reactivity of M2e-specific antibodies generated in M2e and M2e-NSP4 vaccinated mice. Groups of Balb/c mice (n = 9–
10) were immunized with either 10 mg M2e or M2e-NSP4 formulated in CAF-01at days 0, 21, and 42. Serum samples obtained at day 56 after primary
vaccination were analyzed in an ELISA for reactivity against various M2e peptides: M2e consensus sequence, M2e A/Indonesia/560H/2006 (H5N1),
M2e A/Ontario/309862 (H1N1), M2e A/equine/London/72 (H7N7). Results of individual sera are presented; group median titres are indicated by
horizontal bars. *denotes a p-value ,0.05. Data are representative of at least three experiments.
doi:10.1371/journal.pone.0046395.g009
Oligomerized M2e as an Influenza Vaccine
PLOS ONE | www.plosone.org 9 October 2012 | Volume 7 | Issue 10 | e46395
peptides, and no cross-reactivity was observed with avian M2e-
peptides that differed by 3–4 aa from the consensus sequence [8].
The only study that has been successful in demonstrating
protection against an influenza A virus subtype encoding an
M2e differing substantially from the consensus is that of Tompkins
et al. [18]. Their challenge virus differed by five aa and vaccination
protected 80% of the mice against lethal challenge. The antibodies
induced by M2e-NSP4 vaccination could cross-react with M2e-
peptides differing by five aa from the vaccine M2e sequence
(Fig. 9). Upon challenge with H7N7 virus differing by the same
number of aa, the protection of M2e-NSP4 immunized mice was
slightly better than that of M2e peptide immunized mice (Fig. 10);
however, only 60% of the M2e-NSP4 mice were protected. In this
context it should be noted that compared to the challenge virus
used by Tompkins et al., which was of the H1N1 subtype, H7N7 is
considered to be a highly pathogenic subtype [35], and the
neurotropism of H7N7 may be a complicating factor making this
model less optimal when trying to evaluate antibody based
protection.
To conclude, in this study we show that M2e-NSP4 is superior
to M2e-peptide immunization in inducing antibodies against the
native M2 protein. Additionally, the M2e-NSP4 construct is very
cheap and easy to produce in large quantities. In the case where
both vaccines were equally good at providing full protection
against lethal challenge with a virus differing from the vaccine
sequence by one aa, only M2e-NSP4 immunized mice presented
with a significantly reduced early virus load in the lungs.
Moreover, following a reduction in either the number of vaccine
doses or the amount of antigen used for each immunization, M2e-
NSP4 was clearly superior at inducing protective immunity.
Finally, M2e-NSP4 immunization induced antibodies that were
significantly more cross-reactive to non-consensus M2e peptides
and tended to afford better protection against a virus differing by
five aa from the M2e consensus sequence.
Supporting Information
Figure S1 Dose/response comparison of M2e and M2e-
NSP4 immunization. Groups of Balb/c mice (n = 9–10) were
immunized at days 0, 21, and 42 with 10 or 100 mg of M2e
peptide or 10 and 50 mg of M2e-NSP4, both formulated in CAF-
01. Serum samples were obtained 14 days after each vaccination,
i.e. at days 14 (1uvacc), 35 (2uvacc), and 56 (3uvacc) after primary
vaccination and analyzed in an ELISA for reactivity against M2e
peptide. Results of individual sera are presented; group median
titres are indicated by horizontal bars. *denotes a p-value ,0.05.
The results are representative of two experiments.
(TIF)
Figure S2 Comparison of adjuvants. Groups of Balb/c
mice (n = 5) were immunized with 10 mg M2e peptide or M2e-
NSP4 formulated in CAF-01, FIA + FCA, or AlOH at day 0, 21,
and 42. Serum samples obtained on day 56 after primary
vaccination were analyzed in ELISA for reactivity against M2e
peptide. Results of individual sera are presented; group median
titres are indicated by horizontal bars. *denotes a p-value ,0.05.
The data shown are representative of two experiments.
(TIF)
Figure S3 Reactivity of sera from M2e and M2e-NSP4
immunized mice against HeLa cells expressing M2
protein. Balb/c mice were immunized with 10 mg M2e peptide
or M2e-NSP4 formulated in CAF-01 at days 0, 21, and 42.
Binding of antibodies to HeLa cells expressing M2e (HeLa-M2)
and non-expressing control cells (HeLa-C10) was analyzed by
flowcytometry using sera harvested on day 56 after primary
vaccination, representative histograms are presented. Binding of
the M2e-specific monoclonal antibody 14C2 served as a positive
control.
(TIF)
Figure S4 Evaluation of dose of M2e-NSP4 vaccine
required for in vivo protection. Balb/c mice (n = 4–5) were
immunized three times with 3 weeks interval with either 10 mg
M2e-NSP4 with or w/o CAF-01, or 1 or 0.1 mg M2e-NSP4 in
CAF-01. Control mice were left untreated. Around 6 weeks after
the last immunization the mice were infected with 3 LD50 of
influenza virus PR8. The mice were monitored daily with regard
to survival (A) and loss of body weight (B).
(TIF)
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Figure 10. Comparison of M2e and M2e-NSP4 induced pro-
tection against challenge with a distantly related influenza A
virus. Balb/c mice (n = 5–10/group//experiment) were immunized
three times with 3 weeks interval with either 10 mg M2e or 10 mg
M2e-NSP4 in CAF-01. Control mice were left untreated. Around 4 weeks
after the last immunization the mice were infected with 3 LD50 of
influenza virus H7N7, differing by 5 amino acids from the M2e
consensus sequence. Mice were monitored for survival (A) and loss of
body weight (B) daily.
doi:10.1371/journal.pone.0046395.g010
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